SAN CARLOS, Calif.--(BUSINESS WIRE)--Nov. 19, 2002--Natus Medial Incorporated ("Natus") (Nasdaq:BABY), a leading provider of products used to identify and monitor common medical disorders that may occur from the time of conception to a baby's first birthday, today announced the appointment of Ken Ludlum, 49, to its Board of Directors. His appointment brings the number of Directors to six.
Mr. Ludlum brings more than 20 years of financial and strategic business experience to the Natus Board. He currently provides strategic consulting services to venture-backed firms through his company, Ludlum & Co. Previously, he was vice president-international operations and vice president-finance and administration for Endovasix, Inc., a development-stage medical device firm. From 1991 to 2000, he held the positions of vice president-finance & administration and chief financial officer at publicly traded firms Perclose, Inc. (acquired by Abbott Laboratories in 1999), Ribogene, Inc. (currently Questcor Pharmaceuticals, Inc.) and Alteon, Inc. (AMEX:ALT). Prior to that, he was employed in investment banking at Montgomery Securities and Dean Witter Reynolds.
Mr. Ludlum currently serves on the Boards of Directors of Kinetikos Medical, a manufacturer of small joint implants; and formerly served on the boards of Bridgeway Plan for Health, a $100 million HMO; and California Pacific Medical Center, a $350 million multi-campus hospital, where he also served on the finance committee.
"We are extremely fortunate to attract an executive with Ken's experience to our Board," said William New, Jr., M.D., Ph.D., chairman of Natus. "We intend to call upon Ken's considerable strategic business and financial expertise."
Back to Portfolio News